Most recently, APEPTICO’s patent “Prevention and Treatment of Hyperpermeability” was awarded the INVENTUM nomination based on a decision of a jury composed of experts of the Austrian Patent Office and the Federal Ministry for Transport, Innovation and Technology. APEPTICO’s invention ranks among the 10 most innovative inventions of the year 2011 in Austria.
About Apeptico GmbH
APEPTICO Forschung und Entwicklung GmbH is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids any risk of transmitting microbial and viral infections. Development cost and time to market are significantly reduced if compared to the recombinant development process of biomolecules. APEPTICO’s development platform PEPBASETM combines structural, functional and clinical data from relevant biopharmaceuticals and well-characterised proteins. Based on preclinical and clinical data, including adverse reactions, risk factors and contraindications to be circumvented and supported by structural, biochemical and physicochemical data, for each relevant protein a specific profile is established that links biological & functional properties with discrete structural elements.